menu
    • menu
    [{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass Technologies \/ YNC Medical"},{"orgOrder":0,"company":"MigVax","sponsor":"Ourcrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MigVax \/ Ourcrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ Ourcrowd"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International, Inc"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NanoPass Technologies

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            NanoPass Technologies

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inactivated SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : YNC Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nanopass’s Intradermal Injection Platform Proven to Sustain COVID-19 Vaccine Antibodies Using 1/15 of The Do...

                            Details : The results of IMB’s inactivated SARS-CoV-2 vaccine, have shown that the intradermal 3rd boost allowed for robust and sustained (>6mo) immunogenicity with a favorable safety (no fever and only mild injection site redness and swelling).

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 02, 2022

                            Lead Product(s) : Inactivated SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : YNC Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pluri

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment

                            Details : Pre-clinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal in COVID-19 infection.

                            Product Name : PLX Cell

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            December 03, 2020

                            Lead Product(s) : PLX Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SuperTrans Medical

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            SuperTrans Medical

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Mediforum Pharm

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Korean firm invests $2M in SuperTrans Medical

                            Details : SuperTrans is completing a candidate evaluation of COVID-19 therapy based on its transmission technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 04, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Mediforum Pharm

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kamada

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            Kamada

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Kedrion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Po...

                            Details : Kedrion will supply plasma from convalescent COVID-19. Kamada will be responsible for development, manufacturing and distribution of the product in territories not under kedrion’s responsibility.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 27, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Kedrion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MigVax

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            MigVax

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

                            Details : Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 22, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RedHill Biopharma

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opaganib,Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

                            Details : Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.

                            Product Name : Yeliva

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Opaganib,Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Israel Institute for Biological Research

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rVaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Disease...

                            Details : The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : rVaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MigVax

                            Israel arrow
                            Discovery Europe
                            Not Confirmed

                            MigVax

                            Israel arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MigVax-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $100.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            OurCrowd Launches $100 Million Pandemic Innovation Fund

                            Details : First investments to include MigVax - Israeli contender to produce oral coronavirus vaccine, and Sight Diagnostics - rapid, accurate and safe blood test technology in use at hospitals with COVID-19 patients.

                            Product Name : MigVax-101

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : MigVax-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $100.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth